Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
P/E ratio for Abeona Therapeutics Inc. (ABEO)
P/E ratio as of 2023: -1.98
According to Abeona Therapeutics Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.98. At the end of 2022 the company had a P/E ratio of -0.76.
P/E ratio history for Abeona Therapeutics Inc. from 1995 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.98 |
| 2022 | -0.76 |
| 2021 | -0.38 |
| 2020 | -1.65 |
| 2019 | -2.15 |
| 2018 | -5.99 |
| 2017 | -24.16 |
| 2016 | -7.58 |
| 2015 | -6.38 |
| 2014 | -0.25 |
| 2013 | 1.42 |
| 2012 | -0.55 |
| 2011 | -11.36 |
| 2010 | -5.14 |
| 2009 | -2.24 |
| 2008 | -0.48 |
| 2007 | -0.53 |
| 2006 | -0.77 |
| 2005 | -4.95 |
| 2004 | -5.24 |
| 2003 | -10.02 |
| 2002 | -2.09 |
| 2001 | -9.47 |
| 2000 | -10.17 |
| 1999 | -3.68 |
| 1998 | -2.27 |
| 1997 | -0.22 |
| 1996 | -0.10 |
| 1995 | 3.51 |